US Bancorp’s MoonLake Immunotherapeutics MLTX Stock Holding History

US Bancorp’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.5K	Sell	2,079 -244	-11%	-$4.42K	﹤0.01%	2905
2026 Q1	$43.3K	Buy	2,323 +995	+75%	+$16.5K	﹤0.01%	2778
2025 Q4	$17.5K	Buy	1,328 +15	+1%	+$177	﹤0.01%	3131
2025 Q3	$9.41K	Sell	1,313 -1,436	-52%	-$74.8K	﹤0.01%	3332
2025 Q2	$130K	Buy	2,749 +541	+25%	+$22K	﹤0.01%	2301
2025 Q1	$86.3K	Buy	2,208 +1,178	+114%	+$50.8K	﹤0.01%	2456
2024 Q4	$55.8K	Buy	1,030 +161	+19%	+$8.22K	﹤0.01%	2681
2024 Q3	$43.8K	Buy	+869	New	+$40.7K	﹤0.01%	2800
2023 Q4	–	Sell	-3,547	Closed	-$202K	–	4084
2023 Q3	$202K	Buy	+3,547	New	+$196K	﹤0.01%	1822

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

US Bancorp's MLTX Position: Q2 2026 in Review

US Bancorp reduced its MoonLake Immunotherapeutics (MLTX) stake by 11% in Q2 2026, selling an estimated $4.42K and leaving 2,079 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

US Bancorp first reported a position in MLTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $202K in Q3 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

US Bancorp held 2,079 shares of MoonLake Immunotherapeutics worth $40.5K as of Q2 2026.
US Bancorp sold 244 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $4.42K.
MoonLake Immunotherapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2905 holding.
US Bancorp first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 9 quarters since.
US Bancorp's MoonLake Immunotherapeutics position peaked at $202K in Q3 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.